EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

18 November 2025
EMA/CHMP/58471/2024
Human Medicines Division

Mandate, objectives and rules of procedure for the Cancer Medicines Forum

1. MANDATE AND OBJECTIVE

The Cancer Medicines Forum (CMF) has been established since March 2022 to help advance clinical research into optimising cancer treatments and foster high standards in cancer care in the European Union (EU).

The CMF serves as a platform for information sharing and communication on topics relating to treatment optimisation in oncology, focusing on the post-authorisation setting.

It regularly provides information to EMA's Healthcare Professionals Working Party (HCPWP) and Patients and Consumers Working Party (PCWP), which oversee fora (co)-chaired by EMA for information sharing and communication with healthcare professionals', patients' and/or their organisations.

EMA co-chairs the forum with the European Organisation for Research and Treatment of Cancer (EORTC).

The forum aims to help prioritise actions in oncology as part of the European medicines agencies network strategy to 2028 and Academia Collaboration Matrix Action Plan.

Specifically, the objectives are:

- To serve as a direct and official communication channel with the academic community in oncology.
- To identify key research questions and best methodological approach to improve the clinical use of cancer medicines.
- To discuss the uptake of academic work in the wider context of regulatory decision-making in oncology.

This will facilitate the conduct of clinical trials to support treatment optimisation in oncology and ensure that these efforts align with scientific research and public health needs.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

2. COMPOSITION AND RULES OF PARTICIPATION

2.1. Membership

Its members include the learned societies and organisations relevant for oncology.

3. RULES OF PROCEDURES

3.1. Confidentiality arrangements

The Cancer Medicines Forum members shall undertake to act in the interest of patients and public health, bearing in mind any specific interests which could be prejudicial to their independence with respect to the agenda of the meetings and the objectives of the CMF.

When participating in fora and mentioning either CMF, members shall make clear that the views expressed are their own views and not necessarily those of the CMF and use the following disclaimer: 'The views expressed are the personal views of the author/speaker and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agencies or organisations with which the authors are employed or affiliated.'

No specific confidentiality agreements are deemed necessary, participants are selected through eligible organisation.

3.2. Organisation of events

The CMF with the CMF chairs and scientific coordinator will provide information on initiatives that will be available to the wider community and of upcoming events that may be organised by the EMA or by other stakeholders (webinars, stakeholders workshops and symposium, studies, projects). Reference is made to the Internal Guidance event organisation S-CS: https://docs.eudra.org/webtop/drl/objectId/090142b2837a8fbc

Events such as workshops can be organised specifically for the EMA and are open to the public, in which case no confidential information are deemed to be shared or confidential topics are deemed to be discussed. It is expected that the CMF will contribute to the development and organisation of the programme for the events.

3.3. Responsibilities of the CMF chairs

The responsibilities of the CMF Chairs are outlined as follows:

- To be responsible for the efficient conduct of the business of the CMF.
- To agree on the CMF membership and constitution of the CMF, upon consultation with PCWP and HCPWP.
- To identify gaps in the expertise of the CMF and coordinate the expression of interest of members, observes and advisors when needed.
- To agree on the content of the information to be shared with the CMF.
- Prepare the agenda and minutes of the meetings of the working party in consultation with the Co-Chairs.

- To communicate on activities of the CMF such as publication of the minutes of the CMF meetings.
- To regularly share information and update the HCPWP/PCWP on the CMF activities.
- To facilitate the necessary contacts between the working party and the EMA Human Scientific Committees.
- To review the functioning of the CMF from time to time and propose a potential revision of the rules of procedures to the HCPWP and PCWP based on the experience gained, rules which are adopted by CHMP.